Table 1.

Some of the important studies of uveitis associated with SpA.

Study [Reference]	Study Design	Diagnosis/Number of patients	Study outcomes
Vale et al., 20186	Observational retrospective study	SpA/153	Uveitis predominantly occurred in men, and more frequently in HLA-B27 positive patients
Mitulescu et al., 20187	Retrospective study	SpA/67	Patients with AAU and inflammatory back pain should be referred to a rheumatology unit.
Ninan et al., 20178	Hospital based cross sectional	Seronegative /SpA	Uveitis percentage was 16.3%, AS was commonest occurring in 69.3% and 78.3% patients were HLA-B27 positive
Das et al., 201510	Retrospective study	Uveitis of varying etiologies/343	Changing pattern of uveitis in a tertiary institute was reported with highest number of HLA-B27 associated uveitis.
Lee et al., 201711	Retrospective, interventional case series	AS/91	Men preponderance (70%), average onset in the fourth decade, and unilateral manifestation (87.9%) was observed
Bouzid et al. 202031	Retrospective study	SpA/101	First-line sulfasalazine reduced uveitis relapses
van Denderen et al., 201434	Randomized controlled trial	AS/77	Adalimumab treatment. significantly reduced the number of acute uveitis attacks, and the number of attacks per patient
Rudwaleit et al., 201637	Randomized, double-blind and placebo-controlled RAPID-axSpA (NCT01087762)	axial SpA/218	Certolizumab Pegol reduced uveitis flares
Calvo-Río et al., 201638	Multi-center randomized trial	SpA/15	Golimumab is predicted to be useful therapeutic option in refractory SpA-related uveitis